Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $300.5 million.

  • UroGen Pharma's Total Liabilities rose 869.16% to $300.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.5 million, marking a year-over-year increase of 869.16%. This contributed to the annual value of $294.5 million for FY2024, which is 2093.89% up from last year.
  • Latest data reveals that UroGen Pharma reported Total Liabilities of $300.5 million as of Q3 2025, which was up 869.16% from $302.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Total Liabilities ranged from a high of $302.1 million in Q2 2025 and a low of $20.9 million during Q1 2021
  • In the last 5 years, UroGen Pharma's Total Liabilities had a median value of $233.8 million in 2023 and averaged $211.7 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 77362.71% in 2022, then soared by 488.0% in 2024.
  • UroGen Pharma's Total Liabilities (Quarter) stood at $111.3 million in 2021, then surged by 102.08% to $225.0 million in 2022, then rose by 8.24% to $243.5 million in 2023, then rose by 20.94% to $294.5 million in 2024, then grew by 2.02% to $300.5 million in 2025.
  • Its last three reported values are $300.5 million in Q3 2025, $302.1 million for Q2 2025, and $294.1 million during Q1 2025.